Literature DB >> 18293115

Contact tracing for tuberculosis and treatment for latent infection in a low incidence country.

Elisabeth Langenskiold1, François R Herrmann, B L Luong, Thierry Rochat, Jean-Paul Janssens.   

Abstract

OBJECTIVE: To determine the yield of contact tracing after exposure to active tuberculosis (TB) cases in a low incidence area for TB as well as completion rate and tolerance to treatment for latent TB infection (LTBI).
METHODS: Retrospective study based on a database including all patients evaluated in Geneva during contact tracing procedures; review of medical records of contacts for whom treatment of LTBI was indicated.
RESULTS: 3582 subjects were screened over 10 years (on average 4.3 contacts per index case); 8 (0.2%) had active TB. LTBI was detected in 28% of subjects screened. Foreign origin, exposure and contagiousness of index case were predictive of LTBI. Of the 996 subjects with LTBI, files of 705 subjects followed at our centre were reviewed: treatment was indicated in 571 (81%). Side-effects led to interruption of treatment for LTBI in 32 cases (6.9% of subjects treated); 227 subjects eligible for treatment (40%) either refused or stopped treatment, or were lost to follow-up. Completion rate was 67%.
CONCLUSIONS: In a low-incidence environment for TB, contact tracing procedures had a very low yield for detection of active TB cases; acceptance and completion rates for LTBI therapy were in agreement with recent studies..

Entities:  

Mesh:

Year:  2008        PMID: 18293115     DOI: 2008/05/smw-11964

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  8 in total

1.  Management of latent tuberculous infection in Norway in 2009: a descriptive cross-sectional study.

Authors:  A I M Olsen; H E Andersen; J Aßmus; J A Djupvik; G Gran; K Skaug; O Mørkve
Journal:  Public Health Action       Date:  2013-06-21

2.  Lack of household clustering of malaria in a complex humanitarian emergency: implications for active case detection.

Authors:  Hasan Hamze; Rhianna Charchuk; Makelele Katsuva Jean Paul; Kasereka Masumbuko Claude; Mashukano Léon; Michael T Hawkes
Journal:  Pathog Glob Health       Date:  2016-08-25       Impact factor: 2.894

Review 3.  Contact investigation for tuberculosis: a systematic review and meta-analysis.

Authors:  Gregory J Fox; Simone E Barry; Warwick J Britton; Guy B Marks
Journal:  Eur Respir J       Date:  2012-08-30       Impact factor: 16.671

Review 4.  Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.

Authors:  Christopher Pease; Brian Hutton; Fatemeh Yazdi; Dianna Wolfe; Candyce Hamel; Pauline Quach; Becky Skidmore; David Moher; Gonzalo G Alvarez
Journal:  BMC Infect Dis       Date:  2017-04-11       Impact factor: 3.090

5.  Clinical presentation, demographics and outcome of tuberculosis (TB) in a low incidence area: a 4-year study in Geneva, Switzerland.

Authors:  Omar Kherad; François R Herrmann; Jean-Pierre Zellweger; Thierry Rochat; Jean-Paul Janssens
Journal:  BMC Infect Dis       Date:  2009-12-31       Impact factor: 3.090

6.  Evaluation of tuberculosis underreporting in Greece through comparison with anti-tuberculosis drug consumption.

Authors:  Theodore Lytras; Georgia Spala; Stefanos Bonovas; Takis Panagiotopoulos
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

Review 7.  Risk factors for tuberculosis in contact investigations in Rotterdam, the Netherlands.

Authors:  Jesse Eduard Verdier; Sake Jan de Vlas; Inge D Kidgell-Koppelaar; Jan Hendrik Richardus
Journal:  Infect Dis Rep       Date:  2012-04-03

8.  Initiation and completion rates for latent tuberculosis infection treatment: a systematic review.

Authors:  Andreas Sandgren; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anke Stuurman; Anouk Oordt-Speets; Marieke J van der Werf
Journal:  BMC Infect Dis       Date:  2016-05-17       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.